Ref: MHL/Sec&Legal/2019/28

Date: August 06, 2019

To,

Head, Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Head, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1. G Block, Bandra -Kurla Complex, Bandra (East), Mumbai – 400051

Scrip Code: 542650

Script Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, a presentation to analyst / investors as on August 06, 2019 is attached.

Kindly take the same on the records.

Yours faithfully

For Metropolis Healthcare Limited

Jayant Brotash

METROP

The Pathology Specialist

Jayant Prakash Head Legal, Company Secretary & Compliance Officer Membership No.: F6742 Address: Metropolis Healthcare Limited, 250 D, Udyog Bhavan, Hind Cycle Lane, Worli, Mumbai - 400 030



INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555. Email: support@metropolisindia.com | Website: www.metropolisindia.com Central Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

MEDIA RELEASE

GLOBAL ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

AWARDS AND ACCOLADES

Our Company was awarded *Iconic Pathology Lab* Award by Mid-Day Health & Wellness Awards in September 2018

Metropolis received the 'Best Diagnostic Laboratory' in India award at the Women's Health Conference 2019 supported by the Ministry of AYUSH & Ministry of Health & Family Welfare.

Our Company was awarded special jury mention for "*Service Excellence (Diagnostic Centre)*" by FICCI at the Healthcare Excellence Awards 2018

Our Company was awarded for *"Excellence in Customer Service & Delivery"* by Biotrains, 2018

Metropolis Healthcare won the **Best Temperature Controlled Project of the year** at the Cold Chain Summit Awards held in Mumbai, 2018

Metropolis Healthcare honored for *Excellence in Customer Service & Delivery* at the Home Healthcare Summit & Awards 2018

Metropolis Healthcare Limited reports Consolidated Results for Q1FY20

Investor Release

6th August 2019, Mumbai

Metropolis Healthcare Ltd (NSE: METROPOLIS |BSE: 542650) a leading diagnostic service provider today announced its un-audited financial results for the quarter ended 30th June 2019.

Key performance highlights: Q1 2019-20 vs. Q1 2018-2019

Consolidated revenue growth of 15.7% @ 2033 million backed by robust volume growth

Robust operating performance

Growth in total number of patients: 17.7% Growth in number of tests performed: 20.9% Growth in revenue per test: 5.5% as compared to full year FY18-19 Growth in revenue per patient: 5.3% as compared to full year FY18-19

EBIDTA before CSR and Impact of Ind AS 116 @ INR 511 million, 25.15% on revenue (15.4% growth)

Accounting EBIDTA @ INR 550 million, 27.07% on revenue (24.2% growth)

PAT before CSR and exceptional items & Impact of Ind AS 116 @ INR 350 million, 17.2% on revenue (28.3% growth)

Key Growth Parameters: Increasing retail contribution in focus cities and asset light expansion model: In keeping with our plan to increase retail contribution in focus cities, our Q1FY20 revenue from retail contribution stood at 56% (51% in Q1FY19). This has resulted from a well planned expansion strategy and consistently delivering high consumer experience scores. 258 patient touch points have been added in Q1 FY20 registering an 11% growth q-o-q. Five new labs (Green field and Lab on Lease) are operational in Q1FY20. Our network as of Q1 FY20 consists of 124 laboratories and 2536 patient service centres.

Robust Operating Performance: Total patient visits and **total tests performed** have increased from 1.9Mn in Q1FY19 to 2.3Mn in Q1FY20 and 3.6Mn in Q1FY 19 to 4.3Mn in Q1FY20 respectively; registering an excellent growth of 17.7% and 20.9% Y-o-Y.

New wellness initiatives: In Feb 2019, we launched our wellness initiative '*Truhealth*' across 36 cities which to help bolster our position in the fast growing wellness segment. In the first quarter, we have recorded a 40% growth in this segment. Truhealth comprises of mass awareness on the need of preventive healthcare and promotion of customized wellness packages. It is expected that this segment will grow at a CAGR of approximately 20% over the next three years. (*Frost & Sullivan)





Our Company was awarded for *"Best in Health and Fitness"* in the Digital Campaign Awards by LH Insights 2018.

ACCOLADES WON BY OUR KEY MANAGEMENT TEAM

Our Chairman, Dr Sushil Shah was presented with *Lifetime Achievement Award* at Six Sigma Healthcare Excellence Awards

Dr Sushil Shah awarded the Maharashtra Gaurav Award for Distinguished service to the state and outstanding individual achievements.

Our Managing Director, Ms Ameera Shah was featured in

- Listed amongst *Tycoons of Tomorrow* feature by Forbes
 India
- Fortune India's Most Powerful Women in Business feature 2018 & 2017
- Business Today 'Most Powerful Women in Business' feature 2018
- India Today's 8 most powerful change-makers of business world 2018

The company's academic team published 11 scientific papers in National and International Indexed Journals.

MHL group of doctors have done **180 CME/RTM** programs in FY19 thereby sensitizing 6000 plus doctors on new tests and technologies.

MHL Doctors have presented 14 papers and won 12 poster competition run by prestigious healthcare institutions and hospitals across the country

Commenting on the annual results, Ms Ameera Shah, Managing Director of Metropolis Healthcare Ltd said "We are happy to announce our first quarter results for FY20. Q1 is typically a lean quarter for the industry but we have witnessed a healthy revenue and volume growth. *Keeping in line with our growth strategy, we are witnessing an increase* in revenue contribution from our retail business, reflecting patient trust and preference for Metropolis. Strong operating parameters gives us comfort that we are moving in the right direction.

As a newly listed company and as an organisation with a strong sense of purpose, we are committed to working towards a solid governance framework and strong processes and systems. In addition to creating value for all stakeholders, we will continue to walk the extra mile for our patients who trust us during their most anxious moments during illnesses."

Accolades:

Metropolis Healthcare was recently bestowed with Award dè Excelencia – "Service Excellence in Healthcare & Wellness" during the 3rd Annual Global Business Leadership Forum organised by the Asian African Chamber of Commerce.

Metropolis' Global Reference Laboratory in Mumbai received **the GLP** (Good Laboratory Practices) certification from Euro Assessments and Certification Limited, United Kingdom; an important global compliance on quality protocols in laboratories.

Our scientific team won second prize in poster presentation at the "Recent Advances in Rare Diseases conference" held in Bogota, Colombia.

FINANCIAL HIGHLIGHTS

*EBITDA before CSR and Ind As 116. #PAT before CSR, Exceptional items and impact of Ind AS 116

Particulars (Rs. Mn)	Q1 FY20	Q1 FY19	ΥοΥ%
Consolidated Revenue	2,033	1,758	15.7%
Normalized EBITDA*	511	443	15.4%
Accounting EBIDTA	550	443	24.2%
Margins (%)	27.07%	25.21%	
Normalized PAT#	350	273	28.3%
Margins (%)	17.21%	15.52%	

Boiler plate: Metropolis Healthcare Ltd is a leading diagnostics company in India (by revenue, as of March 31, 2018) (Source: Frost & Sullivan) with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 3,487 clinical laboratory tests and 530 profiles that includes advanced tests in diagnosis of cancer, neurological disorders, infectious diseases and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each and every test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade; which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric reliable diagnostic approach and reports.



Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company	Investor Relations Advisors:
METROP VELS The Pathology Specialist Metropolis Healthcare Limited CIN -U73100MH2000PLC192798	SGA Strategic Growth Advisors Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285
Ms. Nadhiya Mali – Corporate Communications Head <u>corpcomm@metropolisindia.com</u> <u>investor.relations@metropolisindia.com</u> <u>www.metropolisindia.com</u>	Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net / sagar.shroff@sgapl.net +91-77383 77756 / +91-9820519303 www.sgapl.net

METROP The Pathology Specialist

Reaching Out RESPONSIBLY Investor Presentation - August 2019



This presentation and the accompanying slides (the **"Presentation")**, which have been prepared by Metropolis Healthcare Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the tire industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Q1FY20 Financial & Operational Performance




Metropolis is a Strong Consumer Focused and Trusted Pathology Brand in the Indian Diagnostics space ...



Quality Focus Large test Menu Customer Centricity Approach Technical & Scientific Team Pan India Presence





Revenue ✓ Revenue grew by 15.7% to Rs. 203.3 Crs as compared to 175.8 Crs in Q1FY19 ✓ Revenue from *domestic grew at 16.7%* for Q1FY20 on Y-o-Y basis & Contribution increased from 94% to 95%. ✓ Wellness growth was at **40%** on Y-o-Y basis. Increasing contribution from 5.5% in FY19 to 6.5% in Q120. \checkmark Revenue growth is primarily driven by volume growth ✓ B2C segment increased from 43% to 45% **EBIDTA*** ✓ Operating EBIDTA margins for Q1FY20 were 25.15% as compared to 25.21% a marginal dip of 6 bps and EBIDTA for the guarter stood at Rs. 51.1 Crs as compared to 44.3 Crs in Q1FY19, a growth of 15.4% ✓ The operating EBIDTA margin excluding Lab on lease would have been 0.9% higher ✓ The Lab on lease contract existing in Q1 FY19 (11 nos.), have moved from 6.5% EBIDTA to 14.5% EBIDTA margin ✓ The new Lab on lease contracts started post Q1 FY19 (12 nos.) have diluted the total lab on lease EBIDTA to 8.8%


PAT#

✓ PAT for the quarter stood at Rs. 35.0 Crs as compared to Rs. 27.3 Crs, *a growth of 28.3%*


On Consolidated Basis; #Excluding (i) Effect of Ind AS 116, (ii) exceptional items (iii) CSR Cost (iv) Share of loss for equity accounted investees








No. of Tests (In Mn.)





Revenue Per Patient (In Rs.)

 +4.8%
 +5.3%

 778
 836

 778
 854

 899

 778

 836

 854

 899

 778

 836

 854

 899

 778

 836

 854

 99

 778

 90

 778

 836

 854

 90

 778

 90

 778

 90

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 91

 92

 93

 94

 94

 95

 95

 96

 97

 91

 91

 91

 92

 93


Revenue Per Test (In Rs.)


- Total patient visit has increased from 1.9 Mn in Q1FY19 to 2.3 Mn in Q1FY20 registering a growth of 17.7% Y-o-Y
- Number of tests performed has increased to 4.3 Mn in Q1FY20 registering a *growth of 20.9%* Y-o-Y
- Revenue per patient has *increased to Rs. 899* as compared to Rs. 854 in
 FY19
- Revenue per test has *increased to Rs.*471 as compared to Rs. 447 in FY19
- Around 40% of super specialized and specialized test contributes to high revenue per test
- International business leads to higher realization per test
- Institutional customers contribute to higher realization per patient

Network Expansion



Laboratory Network







Network Strategy Highlights

Young Individuals Patients Network Asset Light Network Fast Pace of Execution ✓ 6x patients network growth during FY2016-Q1FY20 ✓ 86.72% of the centre network and 17.74% lab ✓ 258 patients touch point added during Q1FY20 a ✓ 71.32% of the existing Individual patients touch network is asset light. growth of 11% Q-o-Q points added between FY2017 & Q1FY20 ✓ Major addition in the labs in Fy19 and Q1FY20 is ✓ 2,166 patients touch points added during FY2016-The average retail centre matures in five years. As \checkmark through lab on lease model which is asset light Q1FY20 the network matures, it is expected to contribute with no capital requirement to short and mid term future growth





B2C Contribution of Total Revenue



- In focus cities, B2C segment grew from Rs. 51.9 Crs to Rs. 62.8 Crs registering a growth of 21%
- B2C segment now contributes 56% of the revenue from Focus cities as compared to 51% in Q1FY19 & 52% in FY19
- Overall revenue from B2C increased from 43% in Q1FY19 to 45% in Q1FY20.
- B2C contribution in the last few years has seen an upward trend owing to:-
 - ✓ Aggressive **network expansion** to go closer to the patient
 - Integrated Brand building campaigns to establish Metropolis as a trusted brand in the mind of consumer and the doctor
 - Building awareness amongst doctors for quality and service differentiators of Metropolis vs the unorganized sector.
 - Obsessively monitoring customer experience and generating a Net
 Promoters Score (NPS) of 90 across the group

Adjusted Profit & Loss Statement



Profit & Loss (Rs. Crs.)	Q1FY20	Q1FY19	Ү-о-Ү
Revenue from Operations	203.3	175.8	15.7%
Cost of Raw Material Consumed	48.2	41.2	
Laboratory Testing Charges	1.5	1.4	
Employee Expenses	47.2	41.5	
Other Expenses	55.2	47.4	
EBITDA before CSR, One-time expenses & Impact of Ind AS 116	51.1	44.3	15.4%
EBITDA (%)	25.15%	25.21%	-6bps
CSR	0.3	-	
Impact of IND AS 116	-4.2	-	
Reported EBIDTA	55.0	44.3	24.2%
EBIDTA (%)	27.07%	25.21%	
Other Income net of Finance Cost	1.3	1.9	
Depreciation	5.0	4.5	
Ind AS 116 Depreciation	3.3	-	
IND AS 116 Finance Cost	1.5	-	
Profit Before Tax before exceptional items and share of equity accounted investee	46.5	41.7	11.6%
Exceptional Items	6.9	-	
Share of loss for equity accounted investee (net of tax)	0.3	0.2	
Profit Before Tax	39.3	41.5	-5.2%
Profit after tax before CSR, exceptional items and Impact of Ind AS 116	35.0	27.3	28.3%
Margin (%)	17.21%	15.51%	
CSR	0.3	-	
Share of Loss for equity accounted investees (net of tax)	0.3	0.2	
Exceptional items	6.9	-	
Impact of Ind AS 116	0.6	-	
Reported Profit After Tax	26.9	27.1	-0.6%
Reported Profit After Tax (%)	13.24%	15.40%	-214 bps

Overview

- > The Ministry of Corporate Affairs notified Ind AS 116 Leases which is applicable from 1st April 2019
- Changes in the Profit & Loss Account
 - Amortization of Right of Use asset and Finance cost on the lease liability substitutes the Lease rental costs above EBIDTA line
- Changes in the Balance Sheet
 - Ind AS 116 introduces a single lessee accounting model and requires lessee to recognize assets (Right of Use) and liabilities for all leases with non-cancellable period of more than twelve months except for low value assets

Coverage & Scope

Coverage under Ind AS 116	Outside the Scope of Ind As 116
Lessee have control of the assets	Service Contract: In case an arrangement has component of service and rent, then service component is excluded and rent component is included
Fixed commitment / Non cancellable commitment	Where there is no fixed commitment: Any commitment based on usage per unit is considered as a variable payment and not a liability
No exit clause	Short-Term Leases (up to 12 months) / Cancellable arrangement / Contains exit clause






Particulars	Impact
Balance Sheet Asset Side	Right to use Asset created as a separate line item under Fixed Asset up to the tune of Rs. 46.74 Crs for the long-term lease liabilities. Overall balance sheet will increase by the amount of asset created for Leases. This will have an impact on ROCE of the company
Balance Sheet Liability Side	Lease liability of Rs. 52.00 Crs created for in favor lessee as against the asset created. This will be written of over the period of lease tenure. Retained Earnings impact of Rs. 3.54 Crs net of deferred tax
Cash Flow Impact	There would be no change in the cash flow of the company due to changes in accounting standards.



Overview

We are Metropolis: The Pathology Specialist







35+ Years of **Credible Operations**

Leading Diagnostic player in India

Presence in 19 States & 210 Cities




4000+ Tests & Profiles



17 Mn Tests & 8.9 Mn Patient Visit in FY19

Journey to Leadership Position






Foundation
1981 to 2001Building Pillars of Business
2001 to 2015Transformation and Expansion
2015 Onwards

Three decades of Delivering Value to Stakeholders











1a. Diagnostic Industry Poised to grow...





1b. Top players to continue to acquire market share of standalone centers





Increased brand awareness amongst patients and customers towards quality, reliability and test accuracy

Large Test menu

Large Test menu by organized diagnostics chains

Factors leading Consolidation

Specialized offerings

Increased awareness of specialized tests, bundled test profiles and wellness packages

Less than 20% of the Diagnostics Sector in India is organized with limited Pan India presence and focus on Quality Parameters in Testing

ostics



Service

+

Scale

Metropolis is amongst the Front runners for Consolidation

Established track record of successful acquisition and integration in India and overseas


Sustainable and Scalable

Business Model

delivering value to all

stakeholders






Wellness

High absolute margin but low volumes


5%

8%















Network Expansion Strategy

- ✓ Focus on Asset Light Model to achieve Geographic Expansion with High Scalability
- ✓ The A-PSC and D-APSC Model allows us to grow our revenues by providing management and branding support while continuing to focus on increased penetration in our PSCs
- ✓ Better Leverage of our Existing Infrastructure by establishing a wider geographic reach which will enable customer base expansion and improvement in profitability matrix
- ✓ Establish strategic partnerships with **3rd Party Patient Service Centers** in India, Africa and Middle East to boost our Geographic reach







Quality protocols following global standards

99.9% of industry labs remain un-accredited with lack of minimum standards in the industry

Best medical talent trained in the Metropolis way

Talent in the industry remains un-trained with no benchmarks of minimum standards

Quality of materials used are USFDA or CE marked

Commonly used materials by industry labs are low quality

Patient experience score as per NPS is at 85% to 90%

Patient experience in industry labs is of poor infrastructure, lack of hygiene and safety and un-professional service

Ethical philosophy of putting patient first

Common practice in industry is to take shortcuts to enhance profit





"Global Lab Accreditations"





- ✓ Mumbai Lab is CAP accredited since 2005 *(College of American Pathologists, global gold standard in laboratory accreditations)
- ✓ NABL Accreditation follows ISO-15189 Standard and is recognized by ILAC & APLAC
- ✓ GRL and 11 RRLs have NABL accreditation.
- ✓ More than 75% reports are generated by accredited labs. Many of our doctor's are assessors, lead assessors for NABL.
- ✓ Some senior doctors are committee members of NABL, WHO, Government & NGO committees.




No. of Audits Conducted by PAC Team



- ✓ PAC Team: Special Pre Analytical Care Team constituted as part of the Quality Assurance Team
- ✓ This team conducts thorough internal audits as per NABL Checklist to ensure compliance for our collection centres and facilities

NPS Score – PSC & Home Service



98.3% 98.5% 98.1% 98.5% 98.2% 98.5% 2013 2014 2015 2016 2017 2018 CAP EQAS — Industry Benchmark


GRL CAP Proficiency Testing Score

7. People are our greatest asset






- New HR Management System for automated processes improving productivity and ensuring availability of employee data on demand
- ✓ System for nurturing second in line high performers
- ✓ Young, energetic and motivated team.
 Over 60% of workforce are millennial
- ✓ Hungry and experienced management team aligned to vision of the company



- ✓ Strong culture equal opportunity workplace
- ✓ Female : Male Ratio = 41:59
- ✓ 4,500 + Highly skilled and motivated Member base



- ✓ Full Fledged Learning Management System that is used for daily training across the Company.
- ✓ Strong scientific team led by expert MD Doctors and pathologists
- ✓ 201 Doctors
- ✓ 2,228 Scientific & Technical Team

8. Leveraging IT for Competitive Advantage







3

Improving Business revenue generation capabilities

- ✓ IBM Watson Campaign Automation will help improve in additional leads and tracking
- ✓ Lead Management system will help improve lead conversion rate
- ✓ Data Analytics model on customer data will improve Cross-Sell and Upsell

Cost Saving & Optimization

- ✓ Launching a Pricing Engine for better Revenue Assurance
- ✓ Payment Platform improving controls in Cash Management Process
- ✓ Network Bandwidth Optimization (SD-WAN)

Improved Operational Efficiency

- ✓ Zero Data Loss; 100% data replication in remote location
- ✓ Implementation of Sample tracking process to Improve Visibility of Customers & Turn Around Time (TAT) of reports.
- ✓ Automating HR processes through HRMS for better tracking and possible productivity.
- ✓ Introduction of Learning Management System to training and development goals.
- ✓ Automated Quality System to track quality standards across the group




Improve Customer Experience

- ✓ Mobility Applications for consumer's ease of access
- ✓ Service CRM implementation will help improve NPS
- Feedback Management will increase percentage of patient providing instant feedback and rating

8a. Digital Transformation to improve efficiency

5






Our information technology system allows us to fully Integrate and Automate processes ranging from **Registration, Bar-Coding and Billing of specimens to Analysis and Reporting of Test Results**







Customer Centricity: In everything we do







Easy to Interpret Test Report

We offer our patients a Detailed Test Report which covers Result Trend Analysis and Patient Specific Interpretations and comments by our Doctors for certain tests and conditions

02

Sample Collection from Doorstep

We have increased scope of our Home Collection service to 197 cities in India



Conclusive Diagnosis

We also have a policy of ensuring Conclusive Diagnosis to our patients, even if it involves incurring additional costs for us, by way of Re-Checks and Reflex testing on alternate technology




Digital Access

We have developed a Mobile Application

- ✓ For scheduling house calls
- ✓ Accessing Test reports
- ✓ Receiving Test Reminders
- ✓ Online requests for Billing Information


Sustainable Growth across Network








Increase B2C sales mix







Established Track Record of Successful Acquisition and Integration


Successful Track Record of Inorganic Strategy : 22 Acquisitions in 15 years



Few of the Acquired Companies	Year of Acquisition	Location	Revenue at the time of acquisition	Revenue for FY19
Sudharma Metropolis Health Services Private Limited	2003	Kerala	Rs. 1.8 Crores	Rs. 50.4 Crores
Golwilkar Metropolis Health Services (India) Private Limited	2006	Pune	Rs. 3.9 Crores	Rs. 38.6 Crores
Desai Metropolis Health Services Private Limited	2008	Surat	Rs. 3.4 Crores	Rs. 32.0 Crores
R.V. Metropolis Diagnostics & Healthcare Centre Private Limited	2008	Bangalore	Rs. 3.6 Crores	Rs. 37.7 Crores
Dr. Patel Metropolis Healthcare Private Limited	2012	Nasik	Rs. 1.8 Crores	Rs. 13.9 Crores
Sanjeevani Rajkot	2017	Rajkot	Rs. 12.0 Crores	Rs. 16.0 Crores

Metropolis has successfully improved the Performance of the Acquired Businesses as well as grow scale of operations, achieve economies of scale and increase operating efficiency thereby improving Market Position





Growing our offering of Test Packages to Increase Revenue Metrics. Customized packages to Institutional Customers and Personalized Packages to Individual Patients are key

Leverage our vast capabilities in Molecular Diagnostics, Oncology, Cytogenic where there is Less Competition and Higher Margins due to Advanced Technology, Skilled Manpower and Complex Processes Involved

Selectively Participate in PPP Tenders in India by leveraging our experience with the execution of the NACO Order. Large opportunities exist in African markets on PPP basis

Targeting healthy individuals with sedentary lifestyles are prone to diseases such as cardiovascular and diabetes ailments. Precision medicine, focus on preventive care, walk-in/direct-to-customer services to drive growth



Expansion

Aggressive Network Expansion to go closer to Patient + Seeding Cities emerging as New Focused Cities

79% of Existing Patient Touch Points added during FY17-19. Maturity of this Young Network will fuel growth

Inorganic Strategy of Expanding Metropolis Reach to more locations in existing cities of presence and new cities


STRENGTHEN METROPOLIS BRAND TO 'BE THE ONLY CHOICE OF PATIENTS'



Historical Financial & Operational Performance

Pan India Presence...





Metropolis Service Network

Metropolis Service Network	FY18	FY19
Laboratories	106	119
Owned PSC's	251	255
Third Party PSC's	879	1506
ARC's	520	575
Total	1756	2455


2,336

575

1,506

255

FY19




Network Strategy Highlights


Young Individuals Patients Network **Asset Light Network Fast Pace of Execution** 79% of the existing Individual patients touch points \checkmark 5.5x patients network growth during FY2016-19 85% of the centre network is asset light \checkmark \checkmark added during FY2017-19 10 of 13 labs added in FY19 via lab on lease model ✓ 1,938 patients touch points added during FY2016- \checkmark The average retail centre matures in five years. As \checkmark which is asset light with no capital requirement 18 the network matures, it is expected to contribute to short and mid term future growth



Revenue (In Rs. Crs.)



Revenue growth for B2C (In Rs. Crs.)



Bolstering Growth in Wellness Segment



Metropolis Wellness revenue contribution for Metropolis is 5.5% which grew at 27% in FY19



This market is expected to grow at a CAGR of 20% over next 3 financial years (Frost & Sullivan)



Customers today are serious about wellness and choose to undergo preventive screening to safeguard their health and diagnose conditions before they turn in to complications




This segment is termed as wellness as opposed to the illness wherein the patient has to undergo tests when they are prescribed tests during sickness




Wellness & Preventive Diagnostics market is 7% to 9% in FY2018 (Frost & Sullivan)





Well growing B2C Mix





B2C contribution in the last few years has seen an upward trend owing to:-

- ✓ Aggressive network expansion to go closer to the patient
- ✓ Integrated Brand building campaigns to establish Metropolis as a trusted brand in the mind of consumer and the doctor
- ✓ Building awareness amongst doctors for quality and service differentiators of Metropolis vs the unorganized sector
- ✓ Obsessively monitoring customer experience and generating an NPS (*Net Promoters Score) of 85 across the group


On Consolidated Basis

*Net Promoter Score is a management tool that is used to gauge the loyalty of a firm's customer relationships


Financial Highlights




Revenue (In Rs. Crs.)




EBITDA (In Rs. Crs.) before CSR and one time share based and other expenses



EBITDA% before CSR and one time share based and other expenses




PAT (In Rs. Crs.) before CSR and one time share based and other expenses



On Consolidated Basis

Financial Highlights





On Consolidated Basis

Profit & Loss Statement



Profit & Loss (Rs. Crs.)	FY19	FY18	FY17	FY16
Revenue from Operations	760.1	643.6	544.7	475.5
Cost of Material Consumed	173.5	145.9	135.1	124.6
Laboratory testing charges	5.6	5.7	2.5	3.1
Total Raw Material	179.1	151.6	137.6	127.7
Gross Profit	581.0	492.0	407.1	347.8
Gross Profit (%)	76.4%	76.4%	74.7%	73.1%
Employee Expenses	172.7	145.8	127.7	108.2
Other Expenses	201.0	168.1	127.5	113.1
BITDA before CSR and one-time share based and other expenses	207.4	178.2	151.9	126.5
EBITDA (%)	27.3%	27.7%	27.9%	26.6%
CSR	0.8	0.8	-	-
Provision for IL&FS Investment	1.4	-	-	-
One-time share based and other payments	5.9	4.8	(2.7)	(3.3)
EBIDTA	199.3	172.6	154.6	129.8
BIDTA (%)	26.2%	26.8%	28.4%	27.3%
Other Income	9.3	11.3	22.9	15.2
Depreciation	20.1	19.2	17.2	16.6
EBIT	188.4	164.7	160.25	128.41
EBIT (%)	24.8%	25.6%	28.9%	26.3%
Finance Cost	0.5	1.2	0.4	0.8
Share of Profit/Loss from JV	(1.4)	0.0	2.7	3.3
Profit Before Tax	186.5	163.5	159.9	127.5
Profit Before Tax (%)	24.5%	24.9%	29.4%	26.8%
Гах	62.9	51.8	52.7	45.6
Profit After Tax	123.6	111.7	107.3	82.0
Profit After Tax (%)	16.3%	17.1%	19.7%	17.2%
CSR	0.8	0.8	-	-
One-time Share based and other expenses	3.6	0.0	-	-
Provision for IL&FS Investment	1.4	-	-	-
Share of Loss for equity accounted investees (net of tax)	1.4	-	-	-
PAT before CSR, one-time share based and other expenses	130.8	112.4	107.3	82.0
PAT before CSR, one-time share based and other expenses %	17.2%	17.5%	19.7%	17.2%

On Consolidated Basis

Balance Sheet



Assets (Rs. Crs.)	Mar-19	Mar-18	Mar-17	Mar-16
Assels (RS. CIS.)	Iviar-19	IVIdI-10		
Non-current assets	248.2	230.1	230.1	170.6
Property, Plant and Equipment	116.7	112.3	105.2	105.6
Capital Work In-Progress	0.0	0.0	1.0	0.6
Goodwill	78.6	78.4	82.5	35.1
Other intangible assets	17.6	16.8	14.7	1.0
Intangible assets under development	5.8	0.0	0.0	0.0
Equity accounted investees	0.6	0.0	6.0	5.4
Financial Assets				
(i) Investments	1.8	1.8	1.8	1.8
(ii)Loans	4.2	3.3	3.7	8.3
(iii) Other Financial Assets	10.2	8.3	2.2	0.0
Deferred Tax Assets (Net)	3.7	5.3	3.4	5.2
Other non-current assets	1.6	2.0	8.6	5.8
Non-current tax assets (net)	7.4	1.9	1.0	1.8
Current assets	304.7	300.4	285.1	225.3
Inventories	26.1	21.2	14.1	15.6
Financial Assets				
(i) Investments	31.0	100.4	134.1	94.2
(ii) Trade receivables	136.8	100.7	80.3	70.2
(iii) Cash and cash equivalents	51.4	43.5	25.5	26.8
(iv) Bank balances other than (iii)	28.9	16.7	15.0	6.8
(v) Loans	15.1	10.8	9.6	7.3
(vi) Other Financial Assets	8.4	1.4	0.5	0.5
Current tax assets (net)			0.1	0.3
Other Current Assets	7.0	5.7	5.9	3.6
TOTAL - ASSETS	552.9	530.5	515. 2	395.9

Equity & Liabilities (Rs. Crs.)	Mar-19	Mar-18	Mar-17	Mar-16
Equity	419.9	429.1	344.1	293.9
Equity Share capital	10.0	9.5	9.5	9.5
Other equity	408.5	405.2	313.6	269.2
Non Controlling Interest	1.4	14.4	21.0	15.2
LIABILITIES				
Non-current liabilities	8.2	10.5	19.3	11.1
Financial Liabilities				
(i) Borrowings	0.0	0.2	0.4	0.5
(ii)Other Non-Current Liabilities	2.1	2.4	8.7	0.3
Provisions	3.2	3.5	3.2	2.4
Deferred tax liabilities (Net)	2.9	4.4	7.0	7.9
Current liabilities	124.8	90.9	151.8	90.9
Financial Liabilities				
(i) Borrowings	17.6	0.4	0.4	0.4
(ii) Trade Payables	42.9	35.4	35.9	32.8
(iii) Other Current Financial Liabilities	41.9	34.8	88.3	22.9
Other Current Liabilities	8.0	7.8	14.1	21.1
Provisions	5.0	4.4	3.7	3.7
Current tax liabilities (Net)	9.4	8.1	9.4	10.0
TOTAL - EQUITY AND LIABILITIES	552.9	530.5	515.2	395.9



Board of Directors and Management Team

Board of Directors





Dr. Sushil Kanubhai Shah Chairman & Executive Director

Holds a bachelor's degree in Medicine and Surgery and a degree of Doctor of Medicine in Pathology and Bacteriology from University of Bombay. More than 3 decades of experience in Pathology business



Ameera Sushil Shah Managing Director

Holds a bachelor's degree in Business Administration from the University of Texas and also completed Owner-President Management Programme from Harvard Business School. More than 2 decades of experience in Pathology business



Mihir Jagdish Doshi Non-Executive Director

Holds a bachelor's degree in Science from New York University and is also a member of the New York State Society of Certified Public Accountants and the American Institute of Certified Public Accountants.



Sanjay Bhatnagar Independent Director

Holds a master's degree in Engineering from Stanford University and also master's degree in business administration from Harvard University



Vivek Gambhir Independent Director

Holds a bachelor's degree in Science & Arts from Lafayette College, Pennsylvania and a master's degree in Business Administration from Harvard University



Milind Shripad Sarwate Independent Director

Holds a bachelor's degree in Commerce from University of Bombay and is an associate of the ICAI, ICSI & ICWA





Vijender Singh Chief Executive Officer

Holds a bachelor's degree in Science from Kurukshetra University and completed an Executive Education Programme from the Indian School of Business, Hyderabad. More than 30 years of experience in business operations & Business Development



Dr. Nilesh Shah President and Chief of Science & Innovation

Holds a master's degree in Engineering from University of Mumbai and a Diploma in Medical Laboratory Technology from K.J Somaiya College of Science. More than 30 years of experience in science & innovation



Tushar Karnik Chief Financial Officer

Holds a bachelor's degree in Commerce from the University of Mumbai and also an associate member of the ICAI. More than 25 years of experience in Finance



Jayant Prakash Head Legal, C.S. and Compliance Officer

Holds a bachelor's degree in Law from the University of Delhi, Master's degree in Business Administration from ICFAI University and fellow member of ICSI. More than 14 years of experience in legal, secretarial and compliance, and investment banking functions



Ameera Sushil Shah Managing Director



2010	"Diagnostic Services Company of the Year" by Frost & Sullivan	
2012	"Outstanding Quality Diagnostic Services" by HIV Congress 2012	
2014	"Most Promising Brand" by the World Consulting and Research Corporation	$ \mathbf{ abla}$
	"Quality Brand" by Quality Brands India	
2015	"Best Diagnostic Company of the Year" at the National Awards for Excellence in Healthcare	
	"Diagnostic Services Company of the Year" by the VCCircle Network	
	"Excellence in Productive Employment Creation" by Business Today	\frown
2018	"Best in Health and Fitness" in the Digital Campaign Awards by LH Insights	– X
	"Excellence in Customer Service & Delivery" by Biotrains	~ ~
	"Service Excellence (Diagnostic Centre)" by FICCI at the Healthcare Excellence Awards	
	"Iconic Pathology Lab Award" by Mid Day Health & Wellness Awards	



For further information, please contact:

Company :

Investor Relations Advisors :



Metropolis Healthcare Ltd. CIN – U73100MH2000PLC192798 Mr. Tushar Karnik - CFO Email Id – <u>tushar.karnik@metropolisindia.com</u>

www.metropolisindia.com

$\mathbf{SGA}^{\mathtt{Strategic Growth Advisors}}$

Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net / sagar.shroff@sgapl.net +91 77383 77756 / +91 98205 19303 www.sgapl.net